Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder

Inclusion Criteria: * Patients with age between 18-75 years. * Patients with chronic kidney disease stage 3 to 5, and concurrent chronic kidney disease mineral and bone disorder. Exclusion Criteria: * Renal artery stenosis, inherent renal malformation, solitary kidney, or malignancy in urinary system. * New fracture in last 3 months. * Active system immunity diseases. * History of liver failure * History of intestinal malabsorption or chronic diarrhea * Treatment with phenobarbital, phenytoin, rifampicin, sucralfate, steroids, digoxin, or other medications that could affect vitamin D metabolism * Primary hyperparathyroidism * Treatment with cinacalcet or other calcimimetic within the past 6 months * Anticipated dialysis within 6 months after randomization * Have an unstable medical condition, defined as having been hospitalized within 30 days before screening, the expectation of recurrent hospital admissions or life expectancy of less than 6 months in the judgment of the investigator * Subject is currently enrolled in, or fewer than 30 days have passed since subject has completed another investigational device or drug study(s); or subject is receiving another investigational agent(s). * Current treatment with vitamin D 50,000 IU * Using glucocorticoid or immunosuppressive agents. * Acute renal dysfunction. * The expected live time is less than 2 years. * Pregnant or lactating woman. * Suffered from acute myocardial infraction, acute congestive heart failure, or stroke in last 6 months. * Patients whose concurrent illnesses, disability, or geographical residence would hamper attendance at required study visit.